摘要
目的探讨抑制血管生成的分子靶向药物酪氨酸激酶抑制剂索拉菲尼治疗晚期肾透明细胞癌的疗效。方法比较在该院接受索拉菲尼治疗的4例与接受生物化疗治疗的12例晚期肾透明细胞癌患者(mRCC),根据12周用药前后的CT检查结果判定疗效。结果索拉菲尼组和生物化疗组患者可测量病灶的平均缩小比值分别为27.3%和3.2%(P<0.05);索拉菲尼组和生物化疗组的疾病控制率分别为100%和41.7%。结论与生物化疗相比,索拉菲尼能够在短期内对转移性肾透明细胞癌具有明显的治疗效果且安全性较高。
[Objective] To assess the effects of tyrosine kinase inhibitor sorafenib in patients with metastatic renal clear-ceU carcinoma（mRCC）. [ Methods ] 4 patients which were treated with sorafenib were compared with 12 cases received biochemotherapy, and the CT results were evaluated by RECIST criteria after 12 weeks. [Results] The measurable lesian＇s mean shrink proportion of the sorafenib and biochemotherapy groups were 27.3% and 3.2%（P 〈 0.05）, respectively. The response rates were 100% and 41.7% respectively. [Conclusion] Sorafenib has better therapeutic effects on mRCC than biochemotherapy and is safe.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2011年第1期149-151,共3页
China Journal of Modern Medicine
关键词
肾癌
转移
索拉菲尼
生物化疗
renal cell carcinoma
metastasis
sorafenib
biochemotherapy
